Fisher & Paykel Healthcare Corp Ltd

Fisher & Paykel’s December 2024 update shows strong dividend performance, stable portfolio weight in Kingfish, and unchanged quality compliance, confirming its role as a reliable respiratory‑care provider.

Fisher & Paykel Healthcare (FPHC) stays a key ASX All‑Markets listing, offering FDA‑cleared respiratory devices that lower ICU stays and costs, with no recent corporate actions yet strong safety and efficacy evidence.

Fisher & Paykel Healthcare’s first‑half earnings jump and revised 2025 outlook reflect strong ICU demand, cost discipline and new FDA clearance, but supply‑chain risks and regulatory changes could curb future gains.

Fisher & Paykel Healthcare Corp Ltd (FYH) has seen a modest up-trend in its share price, with institutional investor Hyperion Asset Management Limited acquiring a 5.18% stake, citing the company’s strong operational metrics and strategic focus on st…

Fisher & Paykel Healthcare Corp Ltd has demonstrated a stable market trajectory, with a moderate uptrend in its share price and a high price-to-earnings ratio, driven by its entrenched presence in the health-care equipment and supply market and robu…

Fisher & Paykel Healthcare Corp Ltd. is expected to report a strong half-year performance, driven by cost discipline, high-margin product growth, and alignment with value-based reimbursement frameworks, despite facing operational challenges and mark…

Fisher & Paykel Healthcare Corp Ltd has reported a modest yet consistent rise in its share price, driven by improved financial health, transparent governance, and a clear strategic roadmap, positioning the company for long-term success in the health…

Fisher & Paykel Healthcare is well-positioned for growth in the anesthesia and respiratory devices market due to its strategic focus and strong reputation for delivering high-quality products.

Fisher & Paykel Healthcare Corp Ltd has reported impressive earnings growth, with a 13% rise in operating revenue and 31% increase in net profit projected for the first half of 2026.

Fisher & Paykel Healthcare Corp Ltd has reported a strong financial performance for the first half of 2026, with a 13% increase in operating revenue and a 31% rise in net profit after tax.